Exosome-Loaded HBB Therapy for Nonviral Sickle Cell Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, such as gene therapies using viral vectors, face challenges including irreversible genomic changes, low transduction rates, immune responses, and ethical concerns, while non-viral methods lack effective drug delivery systems to correct the underlying genetic defect.
Innovation Solution
Development of clinical-grade exosomes extracted from human mesenchymal stem cells or peripheral blood mononuclear cells, loaded with a Hemoglobin Subunit Beta DNA plasmid and siRNA to correct the SNP rs334, expressing normal hemoglobin and blocking mutated sickle cell hemoglobin, using a non-immunogenic and non-toxic approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene therapy, then transduction efficiency is improved, but harmful factors such as immune responses and genomic integration risks increase
Solution Approach 1:
The patent uses exosomes as intermediary carriers to deliver therapeutic genes to target cells, replacing viral vectors as the delivery mechanism. Exosomes serve as a non-viral intermediary that can transport genetic material without triggering immune responses or causing genomic integration, thus resolving the contradiction between transduction efficiency and harmful effects.
Solution Approach 2:
The patent substitutes the viral vector-based delivery system with an exosome-based delivery system. This replacement eliminates the harmful mechanisms of viral integration and immune activation while maintaining the ability to deliver therapeutic genes effectively to target cells.
2Reliability
If chemotherapy is used to treat sickle cell disease, then disease progression is controlled, but harmful effects on bone and brain development occur
Solution Approach 1:
The patent converts the harmful effect of chemotherapy on bone marrow by using exosomes to deliver genes that stimulate endogenous hematopoietic stem cells to produce functional hemoglobin. This approach eliminates the need for cytotoxic chemotherapy while achieving disease control, transforming a harmful treatment into a beneficial regenerative therapy.
Solution Approach 2:
The therapy enables the patient's own bone marrow stem cells to produce functional hemoglobin through exosome-delivered genes, making the body's natural regenerative capacity serve the therapeutic purpose. This self-service mechanism eliminates the need for external cytotoxic agents that harm development.
3Reliability
If bone marrow ablation is performed, then treatment efficacy is improved, but harmful effects on pediatric bone development occur
Solution Approach 1:
The patent uses exosomes as intermediary carriers to deliver therapeutic genes to hematopoietic stem cells, replacing the need for bone marrow ablation. This intermediary delivery system achieves treatment efficacy without the harmful effects of cytotoxic chemotherapy and bone marrow destruction on pediatric development.
Data Source
AI summary
A composition for treating sickle cell disease includes a cGMP exosome having a size range between 60 nm to 120 nm, which may be extracted from a human mesenchymal stem cell (hMSC) or human PBMC at 320,000 g, wherein the cGMP exosome may be loaded with a Hemoglobin Subunit Beta (HBB) DNA plasmid carrying a gene encoding a normal beta chain of hemoglobin and alone or in combination with a short interference RNA (siRNA) that silences the translation of the SNP rs334 (A) mutation of the beta chain of a Hemoglobin A protein.